Status:
COMPLETED
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
Lead Sponsor:
AstraZeneca
Conditions:
Anxiety
Eligibility:
MALE
20-45 years
Phase:
PHASE1
Brief Summary
The study is carried out in order to determine the relationship between the dose of AZD6280 and the blood concentration of AZD6280, and to investigate to which extent AZD6280 binds to GABAA receptors
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg
- Clinically normal physical findings, medical history and laboratory values.
Exclusion
- Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.
- History of clinically significant heart arrythmias or heart disease/problems.
- Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2008
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00681746
Start Date
February 1 2008
End Date
September 1 2008
Last Update
December 10 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Stockholm, Sweden